We are live on ! Find out more
FP

Flagship Pioneering Portfolio holdings

AUM $1.16B
1-Year Est. Return 67.93%
This Fund
S&P 500
This Quarter Est. Return
+45.06%
1 Year Est. Return
+67.93%
3 Year Est. Return
-39.17%
5 Year Est. Return
-45.89%
10 Year Est. Return
–
AUM
$6.24B
AUM Growth
+$751M
Cap. Flow
-$369M
Cap. Flow %
-5.91%
Top 10 Hldgs %
99.02%
Holding
12
New
1
Increased
3
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
SANA icon
Sana Biotechnology
SANA
+$1.11B
2
RUBY
Rubius Therapeutics, Inc
RUBY
+$3.07M
3
KLDO
Kaleido Biosciences, Inc. Common Stock
KLDO
+$2.34M
4
EVLO
Evelo Biosciences, Inc. Common Stock
EVLO
+$1.8M

Top Sells

Rank Stock Value
1
MRNA icon
Moderna
MRNA
+$1.49B

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRNA icon
1
Moderna
MRNA
$21.5B
$2.7B 43.16%
20,581,016
-10,290,508
-33% -$1.49B
SANA icon
2
Sana Biotechnology
SANA
$885M
$1.15B 18.35%
+34,239,018
New +$1.11B
RUBY
3
DELISTED
Rubius Therapeutics, Inc
RUBY
$1.02B 16.34%
38,506,526
+210,000
+0.5% +$3.07M
MCRB icon
4
Seres Therapeutics
MCRB
$48.1M
$302M 4.84%
733,699
– –
EVLO
5
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
$246M 3.95%
1,151,503
+6,500
+0.6% +$1.8M
SGTX
6
DELISTED
Sigilon Therapeutics, Inc. Common Stock
SGTX
$232M 3.71%
797,721
– –
FHTX icon
7
Foghorn Therapeutics
FHTX
$285M
$167M 2.68%
12,674,120
– –
KLDO
8
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
$159M 2.54%
19,575,710
+215,000
+1% +$2.34M
DNLI icon
9
Denali Therapeutics
DNLI
$3.67B
$156M 2.5%
2,730,263
– –
AXLA
10
DELISTED
Axcella Health Inc. Common Stock
AXLA
$59.7M 0.96%
501,937
– –
CDAK
11
DELISTED
Codiak BioSciences, Inc. Common Stock
CDAK
$39.3M 0.63%
2,607,303
– –
SYRS
12
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$22M 0.35%
293,849
– –

Similar funds

AC
AltraVue Capital Bellevue, Washington $1.16B AUM 46.45% 1-Year Est. Return
BI
Bramshill Investments Naples, Florida $1.16B AUM 0.86% 1-Year Est. Return
SCP
Sandhill Capital Partners Buffalo, New York $1.16B AUM 12.37% 1-Year Est. Return
SFG
SNS Financial Group Minneapolis, Minnesota $1.16B AUM 13.88% 1-Year Est. Return
GAB
German American Bancorp Jasper, Indiana $1.16B AUM 25.7% 1-Year Est. Return
AMI
Amica Mutual Insurance Providence, Rhode Island $1.16B AUM 21.34% 1-Year Est. Return
FFP
FourThought Financial Partners Venice, Florida $1.16B AUM 24.95% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return

Flagship Pioneering's Q1 2021 Portfolio in Review

As of Q1 2021, Flagship Pioneering held 12 positions worth $6.24B, up 14% from $5.49B the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Flagship Pioneering withdrew a net $369M in Q1 2021, reducing 1 holding. Its largest reduction was Moderna, cutting an estimated $1.49B.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Flagship Pioneering opened a new position in Sana Biotechnology worth $1.15B.

  • Flagship Pioneering's largest Q1 2021 buy was Sana Biotechnology: 34,239,018 shares worth $1.15B.
  • Flagship Pioneering added most to Rubius Therapeutics, Inc in Q1 2021, an estimated $3.07M increase.
  • Flagship Pioneering's biggest Q1 2021 reduction was Moderna, cutting an estimated $1.49B.
  • Flagship Pioneering's ten largest holdings make up 99% of its $6.24B portfolio in Q1 2021.
  • Flagship Pioneering opened 1 new position and closed 0 in Q1 2021.
  • Flagship Pioneering's portfolio value rose 14% quarter-over-quarter to $6.24B.

Based on Flagship Pioneering's 13F filing for Q1 2021, filed 17 May 2021.